Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mereo Biopharma Group Plc ADR (NQ: MREO )

4.250 +0.260 (+6.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,848,952
Open 4.000
Bid (Size) 4.230 (1)
Ask (Size) 4.300 (34)
Prev. Close 3.990
Today's Range 3.990 - 4.410
52wk Range 1.070 - 4.360
Shares Outstanding 584,908,239
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga

Performance

YTD
+84.78%
+84.78%
1 Month
+43.58%
+43.58%
3 Month
+35.35%
+35.35%
6 Month
+103.35%
+103.35%
1 Year
+197.20%
+197.20%

More News

Read More
MicroMarvel: Mereo BioPharma - Analysts Favorite
Via Talk Markets
Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Why Is Mereo BioPharma Stock Trading Higher Today?
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.